LIAISON PLEX Gram-Negative Blood Culture Assay Catalog No. 20-005-303 Recall
LIAISON PLEX Gram-Negative Blood Culture Assay Catalog No. 20-005-303
FDA recall Class II
Ongoing
FDA lists this Class II recall for LIAISON PLEX Gram-Negative Blood Culture Assay Catalog No. 20-005-303. Review the affected identifiers, reported reason and manufacturer instructions below.
Recall at a glance
- Recall number
- Z-0359-2027
- Recall classification
- Class II
- Enforcement status
- Ongoing
- Initiation date
- Oct 5, 2026
- FDA report date
- Nov 11, 2026
- Quantity in commerce
- 30,168 test cartridges (2,514 Kits)
- Distribution
- See key details
- FDA cause
- Error in labeling
What is being recalled?
LIAISON PLEX Gram-Negative Blood Culture Assay Catalog No. 20-005-303
The retrieved code information does not contain explicit model/GTIN pairs that this publication can reliably map.
Search FDA identifier text
Search a model, catalog, lot or UDI value exactly as printed in FDA’s product description or code information.
This search checks only the FDA product description and code information displayed on this page. It does not decode a UDI, normalize GTIN lengths or establish a relationship between separately listed codes.
FDA code information
All lots UDI-DI pending
Why was this product recalled?
Instructions for Use updated to include explicit guidance that repeat testing is recommended whenever a positive family-level only result is obtained. Issue may contribute to incorrect or delayed diagnosis of bloodstream infection.
What actions did Luminex Corporation take?
On October 5, 2026, the firm began notifying customers via "Urgent Field Safety Notice - Medical Device Recall" letters. Consignees were informed that the current Instructions for Use for the Gram-Negative Blood Culture Assay do not adequately describe interpretation of certain positive family-level results. Specifically, when a positive family-level only result is obtained ("family-level only result" refers to a positive organism family-level detection without an accompanying genus- or species-level identification), repeat testing with the LIAISON PLEX Gram-Negative Blood Culture Assay is recommended. Absence of this instruction may increase the likelihood that certain reportable detections are not appropriately recognized by the user and may contribute to an incorrect interpretation of test results. Customers were instructed to implement the following interpretation guidance: When a positive family-level only result is obtained, repeat testing with the LIAISON PLEX BCN assay is recommended. DiaSorin is updating the Instructions for Use to include the revised guidance. Revised labeling will be provided following implementation of the labeling revision. Please contact Technical Support Services with any questions or concerns at the following phone numbers:1-877-785-2323 (U.S. and Canada); +1-512-381-4397 (Outside U.S. and Canada); 1-512-219-5114 (Fax) and email:support@luminexcorp.com.
Read the manufacturer action recorded by FDARecall timeline
Recall initiated by firm
FDA notice posted
FDA classification recorded
FDA enforcement report date
Related FDA submissions
No submission number with an exact verified relationship is linked in the retrieved recall notice.
FDA’s notice explicitly links the submission numbers shown here. Read each filing for its own recorded device and scope.
Source and update history
- FDA recall notice Z-0359-2027
- openFDA enforcement record · Source release Nov 11, 2026 · Retrieved Nov 19, 2026
- openFDA device recall record · Source release Nov 14, 2026 · Retrieved Nov 19, 2026
- FDA enforcement data
First stored snapshot of this source.
- FDA device-recall notice
First stored snapshot of this source.
The history starts with the versions held by MedtechLedger. Earlier source changes are not reconstructed. Official dates and recorded status come from FDA; page summaries describe the source information.
Our data sources and methodology